Kyle Bass files IPR against patent related to Imbruvica (Ibrutinib)
FiercePharma reports on another IPR filed by hedge funder Kyle Bass against a drug patent. This one relates to the '090 patent on Imbruvica:
--
After Bass' petition was filed Monday, Pharmacyclics shares dropped. Not by a huge amount, as Acorda's did after the Ampyra challenge. But plenty to deliver a significantly bigger profit--provided you were short enough.
--
Ibrutinib was first designed and synthesized at Celera Genomics .
Approved by the FDA for treatment of mantle cell lymphoma, it is being studied for use against other afflictions, including diffuse large B-cell lymphoma and multiple myeloma.
--
After Bass' petition was filed Monday, Pharmacyclics shares dropped. Not by a huge amount, as Acorda's did after the Ampyra challenge. But plenty to deliver a significantly bigger profit--provided you were short enough.
--
Ibrutinib was first designed and synthesized at Celera Genomics .
Approved by the FDA for treatment of mantle cell lymphoma, it is being studied for use against other afflictions, including diffuse large B-cell lymphoma and multiple myeloma.
posted by Lawrence B. Ebert at 4:12 AM
0 Comments:
Post a Comment
<< Home